HeyJaredTher Adv Gastroenterol
- Indexed articles, last 90 days
- 6
- Latest publication
- Aug 5, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 24, 2026
Latest articles
Particle Therapy May Enhance Survival in Pancreatic Cancer (opens the original)
Read excerpt
In patients with unresectable locally advanced pancreatic cancer (LAPC), particle chemoradiotherapy (CRT) achieved a pooled 1-year overall survival (OS) of more than 75% and 2-year OS of more than 40% — comparably higher than rates observed with photon CRT, combination chemotherapy (CT), and single-agent CT. "Particle CRT shows potential as an option of first-line treatment for unresectable LAPC," the authors of the study wrote. The study was led by Cheng-Shien Shieh and Po-Long Cheng, Taipei Me
Water Exchange Colonoscopy Boosts Adenoma Detection (opens the original)
Read excerpt
Water exchange (WE) colonoscopy detected adenomas in 57.9% of colonoscopies compared to 44.0% with air insufflation—an absolute increase of 14 percentage points—with the greatest benefit in the right colon. It also improved bowel preparation quality, at the trade-off of a longer procedure. "An important finding of this study is that the magnitude of benefit (ADR +14.0%) persisted even against a high-performance baseline, where the air insufflation group’s ADR (44.0%) already substantially exceed
Etrasimod Effective As First-Line Advanced UC Therapy (opens the original)
Read excerpt
Compared with placebo, etrasimod demonstrated greater efficacy as a first-line advanced therapy in patients with ulcerative colitis (UC) who escalated treatment following failure of 5-aminosalicylates (5-ASA) alone. The treatment also seemed effective in patients previously exposed to other conventional therapies such as corticosteroids and thiopurines. "Etrasimod thus provides an early advanced treatment option for advanced therapy candidates following conventional therapy failure. Expanded ado
Adalimumab May Help Maintain Remission in Crohn's Disease (opens the original)
Read excerpt
Adalimumab was associated with moderate certainty of evidence for maintaining clinical remission in patients with Crohn's disease (CD). Upadacitinib was linked to high certainty of evidence for preventing loss of clinical response. "Novel therapies seem to have similar effect sizes of efficacy while maintaining good safety records, though imprecision because of limited evidence precludes further conclusions," the authors of the study wrote. The study was led by Vassiliki Sinopoulou, University o
Switch to Budesonide Tablets Improve Remission in EoE (opens the original)
Read excerpt
Patients with eosinophilic esophagitis (EoE) who switched from budesonide viscous solution (BVS) to budesonide orodispersible tablets (BOT) at the same dose and schedule experienced significant improvements in histological and deep histological remission rates. Endoscopic scores also improved significantly, and health-related quality of life (HRQOL) increased, though a numeric rise in endoscopic suspicion of candidiasis was observed. "BOT may be a potential rescue option in patients who fail BVS
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.